Ingredients by Nature receives patent approval for use of eriocitrin to support blood glucose
The U.S. Patent and Trademark Office has approved a patent for the use of eriocitrin in Ingredient By Nature’s ingredient formulations, such as Eriomin, a citrus flavonoid designed for blood glucose support.
Photo © iStockphoto.com/eli_asenova
The U.S. Patent and Trademark Office has approved a patent for the use of eriocitrin in Ingredient By Nature’s (IBN; Montclair, CA) ingredient formulations, such as Eriomin, a citrus flavonoid designed for blood glucose support. The specific patent claim states that eriocitrin can be used as, “A method of reducing blood glucose levels in a human subject in need thereof, comprising administering to the subject a composition comprising 100-200 mg eriocitrin once per day.”
“We couldn’t be happier with the progress we have made to recognize eriocitrin as a viable option for better health,” said Rob Brewster, president of IBN, in a press release. “Supported by a successful first clinical trial and now this patent, our line of Eriomin lemon flavonoid blends, which are primarily comprised of eriocitrin, provide powerful support to managing healthy blood glucose levels. We look forward to revealing additional significant results from ongoing research into the effect that eriocitrin can have on blood glucose levels later this year.”
Senate Committee has released the text of 2024 Farm Bill, with changes to hemp regulations
November 19th 2024The U.S. Senate Committee on Agriculture, Nutrition, & Forestry has introduced the Rural Prosperity and Food Security Act, which will serve as the Senate’s draft for the 2024 Farm Bill.
NPA’s lawsuit against FDA on NMN stayed pending agency’s decision on citizen petition
November 6th 2024The court has granted a joint motion for stay filed by NPA and FDA, pending the agency's decision on the citizen petition asking FDA to reverse its stance on NMN's status as a dietary ingredient.
